A Randomized, Double-Blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.

Trial Profile

A Randomized, Double-Blind Study of the Effect of Treatment Duration and Dose of PEGASYS on HBeAg Seroconversion and Safety in Patients With HBeAg Positive Chronic Hepatitis B.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2013

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms NEPTUNE
  • Sponsors Roche
  • Most Recent Events

    • 01 Nov 2011 Results published in Hepatology.
    • 19 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov. (Parent trial: NCT00435825).
    • 19 Jul 2011 Actual end date (December 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top